The effect of orlistat on body weight in obese Czech adults

• Authors: Vladimír Pavlík , Jana Fajfrová , Eva Drahokoupilová
• Languages of publication: EN

Abstracts

EN

Keywords

EN

Orlistat; Obesity; Pharmacotherapy of obesity; Weight reduction

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 5
• Pages: 553-557

Dates

published

1 - 10 - 2013

online

18 - 9 - 2013

Contributors

author

Vladimír Pavlík

• Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic

author

Jana Fajfrová

• Department of Military Hygiene, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic

author

Eva Drahokoupilová

• Language Training Centre, Faculty of Military Health Sciences, University of Defence, Trebesska, Czech Republic

References

• [1] Reaven P., Metabolic syndrome, J. Insur. Med., 2004, 36, 132–142
• [2] Ginter E, Simko V., Adult obesity at the beginning od the 21st century: epidemiology, pathophysiology and health risk, Bratisl. Lek. Listy, 2008, 109, 224–230
• [3] Waden T.A, Berkowitz R.I, Womble L.G., Randomized trial of lifestyle modification and pharmacotherapy for obesity, N. Engl. J. Med., 2005, 353, 2111–2116 http://dx.doi.org/10.1056/NEJMoa050156[Crossref]
• [4] Svendsen M, Tonstad S., Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders, Nutr. J., 2011, 8, 10–21 [WoS]
• [5] Torp-Pedersen C, Caterson I, Coutinho W., Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial, Eur. Heart. J., 2007, 28(23), 2915–2923 http://dx.doi.org/10.1093/eurheartj/ehm217[WoS][Crossref]
• [6] James W.P, Caterson I.D, Coutinho W., Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects, N. Engl. J. Med., 2010, 363(10), 905–917 http://dx.doi.org/10.1056/NEJMoa1003114[WoS][Crossref]
• [7] Hainer V., Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes Care, 2011, 34, 349–354 http://dx.doi.org/10.2337/dc11-s255[Crossref][WoS]
• [8] Bray G.A., Medical therapy for obesity, Mt. Sinai J. Med., 2010, 77(5), 407–417 http://dx.doi.org/10.1002/msj.20207[Crossref]
• [9] Li Z, Maglione M, Tu W., Pharmacologic treatment of obesity, Ann. Intern. Med., 2005, 142, 532–538 http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00012[Crossref]
• [10] Hainer V., Orlistat a perspektivy farmakoterapie obezity, JAMA, 1999, 7, 371–373
• [11] Li M.F, Cheung B.M., Rise and fall of anti-obesity drugs, World J. Diabetes, 2011, 15(2), 19–23 http://dx.doi.org/10.4239/wjd.v2.i2.19[Crossref]
• [12] Jain S.S, Ramajane S.J, Akat P.B., Evaluation of efficacy and safety of orlistat in obese patients, Indian J. Endocrinol. Metab., 2011, 15(2), 99–104 http://dx.doi.org/10.4103/2230-8210.81938[Crossref]
• [13] Derosa G, Maffioli P, Salvadeo S.A., Comparison of orlistat treatment and placebo in obese type 2 diabetic patients, Expert Opin. Pharmacother., 2010, 11(12), 1971–1982 http://dx.doi.org/10.1517/14656566.2010.493557[Crossref][WoS]
• [14] Minarčíková I., Farmakoekonomické aspekty ve farmakoterapii obezity, Česká a Slov. Farm., 2003, 52, 258–261
• [15] Hainer V., Comment to the article: Assessment of morbid obesity treatment cost efficiency in the Czech Republic, Diab. Metab. Endokr., 2012, 15(3), 199–200
• [16] Russell-Jones D., Gough S. Recent advances in incretin-based therapies, Clin. Endocrinol. 2012, 77(4), 489–499 http://dx.doi.org/10.1111/j.1365-2265.2012.04483.x[WoS][Crossref]
• [17] Hayes M.R., De Jonghe B.C., Kanoski S.E., Role of the glucagon-like-peptide-1 receptor in the control of energy balance, Physiology and Behavior, 2010, 100(5), 503–510 http://dx.doi.org/10.1016/j.physbeh.2010.02.029[Crossref]
• [18] Allison D.B., Gadde K.M., Garvey W.T., Controlledrelease phentermine/topiramate in severely obese adults: a randomized controlled trial, Obesity, 2012, 20(2), 330–42 http://dx.doi.org/10.1038/oby.2011.330[WoS][Crossref]
• [19] Gadde K.M., Day W.W., Low-dose, controlledrelease phentermin/topiramate for reduction of weight, Obesity reviews from 11th International Congress on Obesity, 11–15 July 2010 Stockholm, 2010, 11(1), 42–43
• [20] Ornellas T., Chavez B., A New Approach to Weight Loss in Obese Adults, Pharmacy and Therapeutics, 2011, 36(5), 255–256, 261–262

Identifiers

DOI

10.2478/s11536-013-0194-1